These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 29893894)

  • 1. New developments in systemic therapy for advanced biliary tract cancer.
    Morizane C; Ueno M; Ikeda M; Okusaka T; Ishii H; Furuse J
    Jpn J Clin Oncol; 2018 Aug; 48(8):703-711. PubMed ID: 29893894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-line Chemotherapy in Advanced Biliary Tract Cancer Ten Years After the ABC-02 Trial: "And Yet It Moves!".
    Rizzo A; Brandi G
    Cancer Treat Res Commun; 2021; 27():100335. PubMed ID: 33592561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Durvalumab: A Review in Advanced Biliary Tract Cancer.
    Fung S; Syed YY
    Target Oncol; 2023 Nov; 18(6):965-972. PubMed ID: 37943483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NUC-1031/cisplatin versus gemcitabine/cisplatin in untreated locally advanced/metastatic biliary tract cancer (NuTide:121).
    McNamara MG; Goyal L; Doherty M; Springfeld C; Cosgrove D; Sjoquist KM; Park JO; Verdaguer H; Braconi C; Ross PJ; Gramont A; Zalcberg JR; Palmer DH; Valle JW; Knox JJ
    Future Oncol; 2020 Jun; 16(16):1069-1081. PubMed ID: 32374623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized Phase III study of gemcitabine plus S-1 versus gemcitabine plus cisplatin in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1113, FUGA-BT).
    Mizusawa J; Morizane C; Okusaka T; Katayama H; Ishii H; Fukuda H; Furuse J;
    Jpn J Clin Oncol; 2016 Apr; 46(4):385-8. PubMed ID: 27025903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic therapy for biliary cancers.
    Jordan E; Abou-Alfa GK; Lowery MA
    Chin Clin Oncol; 2016 Oct; 5(5):65. PubMed ID: 27829278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Chemotherapy for Biliary Tract Cancer].
    Woo SM
    Korean J Gastroenterol; 2017 Mar; 69(3):172-176. PubMed ID: 28329919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimum chemotherapy for the management of advanced biliary tract cancer.
    Ghosn M; Kourie HR; El Rassy E; Chebib R; El Karak F; Hanna C; Nasr D
    World J Gastroenterol; 2015 Apr; 21(14):4121-5. PubMed ID: 25892861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Second-line therapies in advanced biliary tract cancers.
    Tella SH; Kommalapati A; Borad MJ; Mahipal A
    Lancet Oncol; 2020 Jan; 21(1):e29-e41. PubMed ID: 31908303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant and neoadjuvant therapy for biliary tract cancer: a review of clinical trials.
    Nara S; Esaki M; Ban D; Takamoto T; Shimada K; Ioka T; Okusaka T; Ishii H; Furuse J
    Jpn J Clin Oncol; 2020 Dec; 50(12):1353-1363. PubMed ID: 33037430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic treatment of advanced or recurrent biliary tract cancer.
    Zhang W; Zhou H; Wang Y; Zhang Z; Cao G; Song T; Zhang T; Li Q
    Biosci Trends; 2020 Nov; 14(5):328-341. PubMed ID: 32830166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of Possible Next Line of Systemic Therapies for Gemcitabine-Resistant Biliary Tract Cancers: A Perspective from Clinical Trials.
    Chiang NJ; Chen LT; Shan YS; Yeh CN; Chen MH
    Biomolecules; 2021 Jan; 11(1):. PubMed ID: 33451059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second-line Treatment in Advanced Biliary Tract Cancer: Today and Tomorrow.
    Rizzo A; Ricci AD; Tober N; Nigro MC; Mosca M; Palloni A; Abbati F; Frega G; DE Lorenzo S; Tavolari S; Brandi G
    Anticancer Res; 2020 Jun; 40(6):3013-3030. PubMed ID: 32487595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of biliary tract carcinoma over the last 30 years.
    Midorikawa Y
    Biosci Trends; 2022 Jul; 16(3):189-197. PubMed ID: 35732436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of chemotherapy in treatments for biliary tract cancer.
    Furuse J; Kasuga A; Takasu A; Kitamura H; Nagashima F
    J Hepatobiliary Pancreat Sci; 2012 Jul; 19(4):337-41. PubMed ID: 22456744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacotherapeutic options for biliary tract cancer: current standard of care and new perspectives.
    Filippi R; Lombardi P; Quarà V; Fenocchio E; Aimar G; Milanesio M; Leone F; Aglietta M
    Expert Opin Pharmacother; 2019 Dec; 20(17):2121-2137. PubMed ID: 31550186
    [No Abstract]   [Full Text] [Related]  

  • 17. NUC-1031, use of ProTide technology to circumvent gemcitabine resistance: current status in clinical trials.
    Kapacee ZA; Knox JJ; Palmer D; Blagden SP; Lamarca A; Valle JW; McNamara MG
    Med Oncol; 2020 Jun; 37(7):61. PubMed ID: 32529264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy: Gemcitabine alone or plus cisplatin for biliary tract cancer?
    Scheithauer W
    Nat Rev Clin Oncol; 2010 Oct; 7(10):554-5. PubMed ID: 20877417
    [No Abstract]   [Full Text] [Related]  

  • 19. Current and emerging therapies for advanced biliary tract cancers.
    Kam AE; Masood A; Shroff RT
    Lancet Gastroenterol Hepatol; 2021 Nov; 6(11):956-969. PubMed ID: 34626563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical aspects and perspectives of erlotinib in the treatment of patients with biliary tract cancer.
    Jensen LH
    Expert Opin Investig Drugs; 2016; 25(3):359-65. PubMed ID: 26781267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.